TY - JOUR T1 - Rapid Sterility Test Systems in the Pharmaceutical Industry: Applying a Structured Approach to their Evaluation, Validation and Global Implementation JF - PDA Journal of Pharmaceutical Science and Technology JO - PDA J Pharm Sci Technol DO - 10.5731/pdajpst.2021.012672 SP - pdajpst.2021.012672 AU - Sven Deutschmann AU - Mousumi Paul AU - Marja Claassen-Willemse AU - Jonas van den Berg AU - Pieta IJzerman-Boon AU - Viviane Grunert da Fonseca AU - Ellen Brunbech AU - Lynn Johnson AU - Chris Knutsen AU - Lucile Plourde AU - Joanny Salvas AU - Philip Villari AU - Lisa Wysocki AU - Margit Franz-Riethdorf Y1 - 2023/01/01 UR - http://journal.pda.org/content/early/2023/01/25/pdajpst.2021.012672.abstract N2 - The current compendial sterility test has a 14-day incubation time and is often the time-limiting step in the Assess and Release Process of pharmaceutical products. There is an ever-increasing number of technologies available on the market that have benefits in addition to faster Time To Result, such as standardization and automation of readout (eliminating analyst subjectivity) and improved data integrity (including eliminating the need for contemporaneous verification of the result by another analyst). Regulators have been encouraging the pharmaceutical industry to adopt these innovative systems; however, it has taken a considerable time before receiving the first approvals from various health authorities (including both EMA and FDA) for the use of an alternative and rapid sterility test for the release of sterile drug product lots. This paper describes a systematic 9-step approach to the evaluation, equipment qualification, validation, and deployment of alternative sterility tests which can be applied by pharmaceutical companies wanting to take advantage of the numerous benefits of alternative sterility tests. Two case studies are presented to illustrate the validation and implementation approach, including statistical methods. While most of the steps towards implementation are aligned, the validation and transfer have been approached differently for each of the case studies because of differences in the chosen technology as well as independent company internal decisions to comply with validation guidelines. However, both case studies show successful implementation of an alternative sterility test for sterile drug products with an ~50% reduced incubation time. ER -